Medicinal chemistry

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #High throughput screening #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Organic chemistry #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics

Technology Innovation Will Help Prepare Drug Discovery for Smart Screening Era

Technology Innovation Will Help Prepare Drug Discovery for Smart Screening Era By Dr Clive Green and Dr Philip Spencer Drug discovery is undergoing a transformation powered by advances that magnitude more molecules and enable smarter selection of compounds. We are on the cusp of having previously unimaginable amounts of information… Read More

#Archive

#ADME / Tox #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Medicinal chemistry #Microbiology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Therapeutics #Toxicology

Discovery and Development of Inhaled Biopharmaceuticals

By Dr Simon Moore, Dr Kirsty Harper & Dr Sylwia Marshall The impact and effective routes of non-clinical safety assessment of inhaled biopharmaceuticals. With the rapid generation of biological screening data and the potential for innovative selection of compounds for screening, the importance of multivendor collaborations together with improvements in… Read More

#Archive

#Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell culture #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Immunology #Medicinal chemistry #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Therapeutic Antibodies – New tools to enhance the antibody drug pipeline

Therapeutic Antibodies - New tools to enhance the antibody drug pipeline By Dr Robert Ford & Dr Toni Hoffmann Therapeutic antibodies are the fastest growing class of drugs, with continuous increases in the number of innovator and biosimilar drugs in development. Drug development and clinical trials necessitate the ability to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Automation / robotics #Business #Cell / tissue culture #Chemistry #Clinical trials #Drug development #Drug discovery #Genetics / genomics #Genomics #High Content Screening #Immunology #Lead discovery #Medicinal chemistry #Patent Law #Regulatory #RNA #Target validation #Therapeutics

Blockchain Technology in Drug Discovery: Use-Cases in R&D

By Dr Richard Shute There is no doubt that the interest and hype around blockchain or distributed ledger technology (DLT) builds daily. The explosion of articles and books recently is testament to this. But what is a blockchain and how might DLT impact healthcare, Pharma and R&D? Running through the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Business #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Imaging #Immunology #Medicinal chemistry #Oncology #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #System biology #Systems biology #Toxicology #Translational #Translational chemistry

Pharma Derisking: Approaches to Reduce Liability to Major Metabolically-Driven Causes of Drug Attrition

Pharma Derisking: Approaches to Reduce Liability to Major Metabolically-Driven Causes of Drug Attrition By Guy Webber Intelligent application of early in vitro testing can help mitigate major drug development risks. The pharmaceutical industry is inherently risky. To develop a molecule that has a desired, efficacious but yet safe effect in… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Genetics #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Microfluidics #Molecular medicine #Organic chemistry #Patent Law #PCR #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

A Strategic Vision For 21st Century Drug Discovery

A Strategic Vision For 21st Century Drug Discovery By Dr Wayne Bowen, Dr Giles Sanders, Dr Andreas Werdich, Dr Brian Warrington and Dr Elizabeth Farrant Delivering genuine therapeutic innovation is more challenging and complex than ever. Despite major scientific breakthroughs and technological advances leading to a greater understanding of the… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Metabolomics #Molecular medicine #Oncology #Organic chemistry #Orphan drugs #Pathology #Pharmacogenomics #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine

Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine By Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu As yesterday’s lead molecule enters today’s clinical trial, the standard operating script seems to call for product developers and clinicians… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Biochemistry #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #High Content Screening #High throughput screening #Immunology #Lead discovery #Medicinal chemistry #Molecular medicine #Oncology #Preclinical #Regulatory #RNA #Screening #System biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Filling the drug discovery abyss

Filling The Drug Discovery Abyss - Novel Business Models to Push Through the Valley of Death By Dr Swati Prasad, Dr Charles McOsker, Professor Kathryn Chapman and Dr Michael Foley Over the past three years, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Business #Cell culture #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #Lead discovery #Medicinal chemistry #Precision medicine #Preclinical #RNA #Target validation #Toxicology

Why Adopting AI is Essential for a Sustainable Pharma Industry

Why Adopting AI is Essential for a Sustainable Pharma Industry By Professor Jackie Hunter Advancements in technology, and in particular, developments in artificial intelligence (AI) are revolutionising the way that we live our lives. Up to now, we have used it to help us find the quickest route home or… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Flow Cytometry #Genetics #High Content Screening #High throughput screening #Imaging #Immunology #Medicinal chemistry #Microfluidics #Molecular medicine #Oncology #Organic chemistry #Pathology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

3D Cellular Imaging – Advances and Considerations for High-Content Screening

3D Cellular Imaging - Advances and Considerations for High-Content Screening By O. Joseph Trask, Dr Daniel V. LaBarbera and Dr Kevin Quick Commercially available high-content imaging (HCI) systems, introduced in the 1990s, have provided the scientific community with a platform that offers a unique set of tools ideal for advancing… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genetics #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Metabolomics #Microbiome #Molecular medicine #Oncology #Patent Law #PCR #Pharmacogenomics #Pharmacokinetics / Pharmacodynamics #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry #Urinary

Reigniting Pharmaceutical Innovation Through Holistic Drug Targeting

By Dr A Roy, Prof B Patwardhan and Dr R Chaguturu Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively holistic. Secondly, none of the… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Patent Law #PCR #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics

The California Institute for Regenerative Medicines Human iPSC Initiative

The California Institute for Regenerative Medicines Human iPSC Initiative By Dr Thomas J. Novak This article discusses large-scale generation of patient-derived induced pluripotent stem cells (iPSCs) to accelerate the understanding of disease biology and drug discovery. In 2012, the California Institute for Regenerative Medicine (CIRM) announced its Human iPSC Initiative,… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Chemistry #Computational chemistry #Drug discovery #Drug targets #Lead discovery #Lead optimisation #Medicinal chemistry

When Two Are Not Enough: Lead Optimisation Beyond Matched Pairs

When Two Are Not Enough: Lead Optimisation Beyond Matched Pairs By Dr Noel M. O'Boyle, Dr Roger A. Sayle and Dr Matt Segall Lead optimisation projects progress by making successive enhancements to one or more starting structures. This is a classic multi-objective optimisation procedure where the goal is not only… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Business #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Enabling technologies #High Content Screening #Lead discovery #Medicinal chemistry #Regulatory #RNA #System biology #Systems biology #Translational #Translational chemistry

Managing Data Challenges In The New R&D Environment

Managing Data Challenges In The New R&D Environment By Dr Paul Denny-Gouldson The discovery and development of drugs is changing. The realm once dominated by ‘big pharma’ is becoming increasingly fragmented into more agile and flexible consortia. The dramatic change of focus on drug type from small molecule to large… Read More

#Archive

#Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Medicinal chemistry #Molecular medicine #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

The Development of Cell-Based Assays For Pain Drug Discovery

Share Share Tweet Email The Development of Cell-Based Assays For Pain Drug Discovery The Development of Cell-Based Assays For Pain Drug Discovery By Dr Paul Karila and Dr Charlotta Blom Since the completion of the Human Genome Project and the beginning of the so-called genomics era in the 1990s, a… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell culture #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Organic chemistry #Orphan drugs #Pharmokinetics #Preclinical #RNA #Screening #Target validation #Toxicology

BioPharma and CROs Collaborating In Early Drug Discovery

BioPharma and CROs Collaborating In Early Drug Discovery By Dr John Montana and Cornelis E.C.A. Hop BioPharma and CROs are riding the latest wave - discovery research - together with a vigour and gusto that might have seemed implausible five years ago. How these collaborations are structured, and how well… Read More

#Archive